Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment
Authors' conclusion
Hyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI-induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.
Study context
- Population
- People receiving an ICI for melanoma, lung or renal cancer
- Participants
- 959 people
- Exposure
- Diabetes at baseline vs no baseline diabetes
- Diabetes at baselinen = 103
- Outcome
- Hyperglycaemia (≥1 glucose ≥11.1 mmol/L)
- Follow-up
- Year after starting an ICI
Methodological detailsretrospective review of electronic records
- Retrospective review of electronic records
Main finding
As reported in the abstract
- Overall with hyperglycaemia
- 131
Observational data: associations, not effects.
Further findings
Baseline diabetes prevalence
- Diabetes at baseline
- 103 (10.7%)
- Lung cancer had the highest frequency of diabetes
Cause of new-onset hyperglycaemia (without pre-existing diabetes), n = 74
- Steroid-induced diabetes
- 76%
- ICI-induced diabetes resembling T1D
- 9.5%
Original publication
Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabet Med. Published 6 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →